Low costs lure R&D, but critics doubt product safety
Big Pharma is testing more drugs in China, where studies cost less and a big, aging population has more chronic ailments, Time
reports. But critics question the country's product safety and ponder the fate of tested patients. Even Big Pharma is concerned—about intellectual property rights—but the lure of...